Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
ALD: Update on the share buyback program
ALD: Update on the share buyback program
ALD: Update on the share buyback program
Voltalia includes a purpose in its articles of incorporation
Voltalia includes a purpose in its articles of incorporation
Voltalia includes a purpose in its articles of incorporation
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
RUBIS: Publication of 2019 Universal registration document
RUBIS: Publication of 2019 Universal registration document
RUBIS: Publication of 2019 Universal registration document
ALD: Q1 2020 Trading Update
ALD: Q1 2020 Trading Update
ALD: Q1 2020 Trading Update
Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM
Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM
Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM
RUBIS: Preparatory documents for the Ordinary Shareholders' Meeting of June 11, 2020
RUBIS: Preparatory documents for the Ordinary Shareholders' Meeting of June 11, 2020
RUBIS: Preparatory documents for the Ordinary Shareholders' Meeting of June 11, 2020
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Showroomprive.com: PUBLICATION OF THE 2019 UNIVERSAL REGISTRATION DOCUMENT, INCLUDING THE 2019 AUDITED CONSOLIDATED FINANCIAL STATEMENTS
Showroomprive.com: PUBLICATION OF THE 2019 UNIVERSAL REGISTRATION DOCUMENT, INCLUDING THE 2019 AUDITED CONSOLIDATED FINANCIAL STATEMENTS
Showroomprive.com: PUBLICATION OF THE 2019 UNIVERSAL REGISTRATION DOCUMENT, INCLUDING THE 2019 AUDITED CONSOLIDATED FINANCIAL STATEMENTS
RUBIS: Infrastructure fund I Squared Capital and Rubis finalise their partnership in Rubis Terminal
RUBIS: Infrastructure fund I Squared Capital and Rubis finalise their partnership in Rubis Terminal
RUBIS: Infrastructure fund I Squared Capital and Rubis finalise their partnership in Rubis Terminal
Showroomprive.com: SHORT AND MEDIUM-TERM FINANCIAL STRUCTURE STRENGTHENED
Showroomprive.com: SHORT AND MEDIUM-TERM FINANCIAL STRUCTURE STRENGTHENED
Showroomprive.com: SHORT AND MEDIUM-TERM FINANCIAL STRUCTURE STRENGTHENED
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
Voltalia buys Nordex turbines for its new VSM 4 wind farm of 59 megawatts in Brazil
Voltalia buys Nordex turbines for its new VSM 4 wind farm of 59 megawatts in Brazil
Voltalia buys Nordex turbines for its new VSM 4 wind farm of 59 megawatts in Brazil
Voltalia SA: Availability of the preparatory documents for the General Meeting of shareholders, to be held in camera without the physical attendance of the shareholders. The presentation (in French) will be webcast on the company's website.   
Voltalia SA: Availability of the preparatory documents for the General Meeting of shareholders, to be held in camera without the physical attendance of the shareholders. The presentation (in French) will be webcast on the company's website.   
Voltalia SA: Availability of the preparatory documents for the General Meeting of shareholders, to be held in camera without the physical attendance of the shareholders. The presentation (in French) will be webcast on the company's website.   
Pharnext Reports Financial Results for Year-End 2019
Pharnext Reports Financial Results for Year-End 2019
Pharnext Reports Financial Results for Year-End 2019
Voltalia SA: Q1 2020 revenue growth of 47%, at constant currency - Ambitions maintained, in a less predictable environment  
Voltalia SA: Q1 2020 revenue growth of 47%, at constant currency - Ambitions maintained, in a less predictable environment  
Voltalia SA: Q1 2020 revenue growth of 47%, at constant currency - Ambitions maintained, in a less predictable environment